Ocaliva Lawsuit Settlement Amounts [2026 Estimates & Projections]

Estimated Ocaliva Lawsuit Settlement Range

At this stage, the estimated Ocaliva lawsuit settlement range remains broad, with early projections falling around $75,000 to $250,000+ depending on the facts of the case.

That range is not based on any reported Ocaliva payouts, but on the types of injuries now being examined and the way severe pharmaceutical injury claims are often valued in early litigation.

Cases involving serious liver damage, repeated hospitalization, or documented liver decline may be viewed very differently from claims involving more limited complications.

Potential value may also depend on whether the evidence suggests the drug contributed to accelerating liver disease progression beyond what physicians would have otherwise expected.

The highest-value claims may involve catastrophic outcomes, including transplant-related injuries and fatal liver failure.

The sections below break that range down further by injury severity, medical proof, and the long-term impact on the person or family bringing the claim.

Projected Range for Moderate Liver Injury Claims

Some projected Ocaliva claims may fall into a lower settlement tier when the reported injury involves impaired liver function without transplant, liver failure, or another catastrophic outcome.

In this context, the estimated range may begin around $50,000 to $100,000, though no public Ocaliva settlements have been reported and any figure remains an early projection only.

These cases may involve less serious liver complications that still required medical attention, medication changes, or follow-up care after concerns about Ocaliva’s risks emerged.

Even in moderate claims, case value may depend heavily on whether medical experts can connect the person’s decline to the drug rather than the expected course of disease in PBC patients.

This category does not mean the injury was minor, only that the long-term damage, financial losses, and overall medical burden may be more limited than in higher-value claims.

Medical records and expert review may focus on factors such as the following:

• Documented impaired liver function after Ocaliva use
• Less serious liver complications that did not lead to transplant or death
• Medication discontinuation, monitoring, or short-term treatment changes
• Medical records showing a change from baseline liver status
• Expert review addressing whether Ocaliva’s risks contributed to the injury in PBC patients

Projected Range for Severe Liver Injury Claims

Some projected Ocaliva claims may fall into a higher tier when the evidence points to significant liver injury rather than a more limited change in liver function.

In this category, an estimated range of $100,000 to $200,000 may apply in early projections, though no public Ocaliva settlements have been reported and these figures remain speculative.

These cases may involve a rapid decline in liver health, more substantial treatment needs, and a stronger argument that the drug contributed to worsening complications beyond the expected course of disease.

The value of these claims may increase when the records show more serious disruption affecting the liver and bile ducts, particularly in cases involving life-threatening liver complications.

Medical records and case review may focus on factors such as the following:

• Significant liver injury requiring hospitalization or intensive follow-up care
• A rapid decline after Ocaliva treatment began or after the dosage continued despite worsening symptoms
• Imaging, labs, or physician notes showing worsening liver and bile ducts function
• Complications suggesting a more dangerous course than ordinary disease progression
• Evidence involving patients with advanced cirrhosis taking Ocaliva despite known safety concerns
• Expert analysis on whether the drug contributed to life-threatening liver complications

This projected range still depends on medical proof, causation evidence, and the person’s long-term outcome.

Claims involving transplant, permanent disability, or death would likely be evaluated in a higher category.

Projected Range for Liver Transplant Claims

Claims involving Ocaliva users who required a liver transplant may fall into one of the highest projected settlement tiers because transplantation reflects a profound and life-altering medical outcome.

In this category, an early estimated range of $150,000 to $200,000+ may apply, though no public Ocaliva settlements have been reported and any figure remains a preliminary projection only.

These cases often involve acute liver failure, severe hospitalization, and long-term medical consequences that extend far beyond the initial injury.

Potential value may also rise where the records suggest worsening liver injury after treatment began, especially when the person’s condition progressed toward permanent organ damage.

In some cases, the central dispute may be whether the transplant became necessary because of the expected course of advanced liver disease or because Ocaliva contributed to an additional and avoidable decline.

That question will likely depend on detailed medical records, treating physicians, and expert review of how the injury developed over time.

Projected Range for Wrongful Death Claims

Wrongful death claims may represent the highest projected tier in this litigation because they involve the loss of a person who was prescribed Ocaliva and later allegedly developed liver injury that proved fatal.

In this category, early projections may begin at $200,000+, though no public Ocaliva settlements or verdicts have been reported and any estimate remains speculative.

These cases may involve allegations that the drug contributed to fatal liver failure, transplant-related complications, or another irreversible decline that ended in death.

The projected value of these claims may depend on the available medical evidence, the age and circumstances of the person who died, and the financial and personal losses suffered by surviving family members.

Some of the most complex cases may include liver transplant death claims, where the medical timeline involves both severe intervention and an alleged fatal outcome.

Case review in wrongful death claims may focus on factors such as the following:

• Whether the person was prescribed Ocaliva before the fatal decline
• Medical records showing the person developed liver injury after treatment began
• Evidence of hospitalization, liver failure, or transplant-related complications before death
• The extent of economic losses and support previously provided to family members
• Testimony from treating physicians and experts about causation
• Whether surviving relatives may seek compensation through a wrongful death lawsuit

These cases are often fact-intensive and may require careful review of the full treatment history, including liver function testing, hospital records, and end-of-life care.

They may also involve legal questions about who has the right to bring the claim and what categories of damages may be available under the applicable state law.

Because of that, wrongful death projections should be presented cautiously and tied to the specific facts of the case rather than any assumed average payout.

Important Notes About Ocaliva Lawsuit Settlement Projections

Any discussion of Ocaliva lawsuit settlement projections should be read with caution because the litigation remains in an early stage and no public settlement history exists.

These figures are not guarantees, promises, or average settlement amounts.

They are only broad estimates meant to help readers understand how claim value may differ based on injury severity, medical proof, and long-term losses.

Ocaliva claims are still developing, and case values may change as litigation progresses through the legal process.

That is especially true in pharmaceutical cases, where case strength often turns on expert review, disputed causation, and evolving evidence.

For that reason, responsible defective drug attorneys do not present projected values as fixed outcomes.

Important points to keep in mind include the following:

• These figures are not guarantees, promises, or average settlement amounts
• Ocaliva claims are still developing, and case values may change as litigation progresses
• Early projections are based on general injury categories, not actual reported Ocaliva payouts
• A stronger case usually depends on detailed medical records, timing, and expert analysis
• Severe outcomes such as transplant or death may be valued differently than less extensive injuries
• The legal process may affect both timing and potential compensation in ways that cannot yet be predicted

Why Ocaliva Lawsuits Are Being Reviewed

Ocaliva (obeticholic acid) was a prescription medication approved to treat primary biliary cholangitis, or PBC, in certain adults, but its regulatory history became increasingly tied to reports of severe liver-related complications.

FDA said in December 2024 that it had identified cases of serious liver injury in some Ocaliva patients without cirrhosis and advised close monitoring for worsening liver function.

In 2025, Ocaliva was withdrawn from the U.S. market after years of escalating safety concerns, and Intercept states the drug was officially removed from the U.S. commercial market on November 14, 2025.

FDA’s withdrawal record says the postmarketing trial did not verify clinical benefit and identified an excess of liver transplants and deaths among certain Ocaliva-treated PBC patients, which is central to current scrutiny over the drug’s liver impairment risks.

The current lawsuit investigation focuses on whether Intercept Pharmaceuticals gave inadequate warnings and whether there was a failure to warn patients and healthcare providers about the severity of those risks as evidence developed.

Claim investigations now commonly center on allegations involving liver failure, transplant, hepatic decompensation, and death after Ocaliva use.

As of early 2026, there have been no publicly announced settlements or jury verdicts involving Ocaliva (obeticholic acid), which means the litigation is still at a very early stage.

If filings continue to grow, Ocaliva cases could eventually be consolidated into multidistrict litigation, though no mature MDL settlement framework exists at this point.

FDA Safety Communications and Regulatory Events Involving Ocaliva

Ocaliva (obeticholic acid) was approved by the US Food and Drug Administration (FDA) in 2016 as a second-line therapy for certain patients with primary biliary cholangitis who did not respond adequately to ursodeoxycholic acid.

Over the following years, the agency issued multiple drug safety communication notices describing serious liver-related adverse effects associated with the medication.

Early warnings focused on incorrect dosing in patients with advanced cirrhosis, which FDA linked to cases of liver failure and death.

Subsequent safety reviews expanded those concerns to include severe liver injury in some patients without cirrhosis.

FDA eventually added a boxed warning and later restricted the drug’s use in patients with advanced liver disease after reports of worsening liver injury.

Post-marketing data also showed higher rates of liver transplant and death among some Ocaliva users compared with placebo in a required clinical study.

Regulatory developments involving Ocaliva include:

• 2016: FDA approves Ocaliva as a second-line therapy for primary biliary cholangitis.
• 2017: FDA issues a drug safety communication warning that incorrect dosing in cirrhotic patients can cause serious liver injury.
• 2018: FDA requires a boxed warning describing the risk of severe liver injury in certain patients.
• 2021: FDA restricts Ocaliva use in patients with advanced cirrhosis after additional safety reports.
• 2024: FDA reports post-marketing evidence showing serious liver injury in some patients without cirrhosis, including cases of liver transplant and death.
• 2025: Ocaliva is withdrawn from the U.S. market after FDA determines the drug’s risks outweigh its benefits.

FDA communications, clinical trial findings, and post-marketing reports documented serious liver injury associated with the medication.

These regulatory actions form part of the factual record being examined in ongoing Ocaliva lawsuit investigations.

No publicly announced settlements or jury verdicts have been reported in lawsuits involving Ocaliva (obeticholic acid).

Do You Qualify for the Ocaliva Lawsuit?

You may qualify for the Ocaliva lawsuit if you took the drug and later developed serious liver-related complications that were not expected from the ordinary course of your condition alone.

Many claims now under review involve allegations of liver failure, hepatic decompensation, transplant-related injury, or death after Ocaliva use.

A potential case may be stronger when medical records show a decline after treatment began, especially where physicians documented abnormal labs, hospitalization, or other warning signs of worsening liver function.

Eligibility may also depend on whether the evidence suggests the drug contributed to the injury rather than only reflecting the underlying progression of primary biliary cholangitis.

People who required emergency treatment, transplant evaluation, or long-term follow-up care may have claims worth reviewing more closely.

Families who lost a loved one after Ocaliva treatment may also have grounds to pursue compensation through a wrongful death claim, depending on the facts and the applicable law.

Because these cases are medically complex, qualification often turns on treatment history, timing, and expert review of causation.

TorHoerman Law is speaking with individuals and families to evaluate whether the facts support filing an Ocaliva lawsuit.

Gathering Evidence for an Ocaliva Lawsuit

Gathering evidence for an Ocaliva lawsuit starts with building a clear record of how the medication was prescribed, how symptoms developed, and how the resulting injuries were diagnosed and treated.

The first step in pursuing an Ocaliva lawsuit is to collect the relevant medical records, prescription history, and treatment timeline.

Attorneys typically review that documentation to assess whether Ocaliva may have contributed to liver decline or other serious health complications, rather than the outcome reflecting only the expected course of the underlying disease.

The stronger and more complete the file, the easier it becomes to build a reliable timeline and show when the injury emerged, how it progressed, and what treatment followed.

That includes records showing whether the patient reported unexpected or worsening symptoms, since patients were repeatedly advised to alert their providers so monitoring and intervention could be arranged.

Strong evidence also helps show the seriousness of the injury, the treatment burden, and the losses connected to the claim.

Our firm can help collect and review these materials as part of the intake process.

Evidence in an Ocaliva lawsuit may include the following:

• Pharmacy and prescribing records showing when Ocaliva was started, adjusted, or discontinued
• Medical records documenting the patient’s condition before treatment and any later decline
• Liver function tests, imaging, biopsy results, and other diagnostic studies
• Hospital records involving liver failure, hepatic decompensation, or other acute complications
• Physician notes describing worsening symptoms, abnormal findings, or concern about drug-related injury
• Records showing whether unexpected or worsening symptoms were reported to treating providers
• Transplant evaluation records, transplant listing records, or transplant surgery records
• Billing records and treatment summaries showing the extent of medical care required
• Employment and income records showing time away from work or reduced earning capacity
• Death records, autopsy findings, and end-of-life records in wrongful death cases

Damages in Ocaliva Liver Injury Lawsuits

Damages are the categories of loss a plaintiff may seek to recover in a lawsuit after an injury allegedly caused by a drug.

In an Ocaliva case, lawyers assess damages by reviewing the person’s medical history, the severity of the liver-related injury, the treatment required, and the effect the condition had on daily life and long-term health.

That analysis usually begins with direct financial losses such as medical expenses and lost wages, then expands to less easily measured harm such as physical pain, emotional distress, and reduced quality of life.

Lawyers also look closely at symptoms that may reflect the burden of the injury, including weakness, repeated hospitalization, and extreme fatigue that interferes with ordinary activities.

In more serious cases, damages may also involve death-related losses and, in some circumstances, allegations supporting punitive damages.

The goal is to build a damages model that reflects both the economic impact of the injury and the human consequences behind claims for pain and suffering.

Potential damages in an Ocaliva lawsuit may include the following:

• Past and future medical expenses
• Lost income and reduced future earning capacity
• Lost wages tied to hospitalization, treatment, or disability
• Physical pain and pain and suffering
• Emotional distress and reduced quality of life
• Costs associated with long-term care or monitoring
• Wrongful death damages for eligible surviving family members
• Punitive damages, where the facts and applicable law support that remedy

TorHoerman Law: Investigating the Ocaliva Lawsuit

Ocaliva lawsuits are still in the early stages, but the growing body of regulatory findings and patient reports has led to increased scrutiny of the drug’s safety profile.

Individuals who experienced serious liver complications after taking Ocaliva may have questions about whether the medication contributed to their injury and what legal options may exist.

These cases often require a careful review of prescription history, medical records, and the progression of liver-related symptoms over time.

TorHoerman Law is reviewing potential Ocaliva claims involving liver injury, transplant-related complications, and wrongful death.

If you or a loved one experienced serious health complications after taking Ocaliva, speaking with an attorney may help determine whether the circumstances support a legal claim.

Contact us today for a free consultation.

You can also use the chat feature on this page for a free, confidential case evaluation.